title: Atherogenic dyslipidemia in patients with established coronary artery disease.
abstract: OBJECTIVE
  Patients with stable coronary heart disease (CHD) and atherogenic dyslipidemia (AD) have a high-risk of recurrence and are those who derive most benefit from treatment with lipid-lowering agents. The aim of this study was to examine the prevalence of AD in patients with stable coronary heart disease and to investigate associated factors.
  
  
  METHODS
  Cross-sectional study involving 7823 subjects admitted for a coronary event between 6 months and 10 years previously. AD was considered to be the concurrent presence of low HDL-cholesterol (<1.03 mmol/L [40 mg/dL] in males, <1.29 mmol/L [50 mg/dL] in females) and elevated triglycerides (≥1.7 mmol/L [150 mg/dL]).
  
  
  RESULTS
  Mean age was 65.3 (10.1) years, 73.6% were males and 80.3% were receiving treatment with statins. Low HDL-cholesterol was observed in 26.3% of the participants, 39.7% had elevated triglyceride concentration and 13.0% had AD. The percentage of AD in patients with criteria for metabolic syndrome was 30.9%. Factors associated directly and independently with the presence of AD in the multivariate analysis were female sex, history of coronary syndrome without ST elevation or coronary revascularization, presence of atrial fibrillation, body mass index, LDL-cholesterol, systolic blood pressure and blood glucose levels, while age and glomerular filtration rate were significantly and inversely associated with AD.
  
  
  CONCLUSIONS
  A significant proportion of patients with coronary disease could benefit from interventions aimed at increasing HDL-cholesterol and reducing triglycerides.
authors.affiliation: Unidad de Arteriosclerosis, Hospital Carlos III, Sinesio Delgado 10, 28036 Madrid, Spain. clahoz.hciii@salud.madrid.org
authors.forename: C
authors.initials: C
authors.lastname: Lahoz
authors.forename: J M
authors.initials: JM
authors.lastname: Mostaza
authors.forename: S
authors.initials: S
authors.lastname: Tranche
authors.forename: R
authors.initials: R
authors.lastname: Martin-Jadraque
authors.forename: M T
authors.initials: MT
authors.lastname: Mantilla
authors.forename: I
authors.initials: I
authors.lastname: López-Rodriguez
authors.forename: B
authors.initials: B
authors.lastname: Monteiro
authors.forename: M A
authors.initials: MA
authors.lastname: Sanchez-Zamorano
authors.forename: M
authors.initials: M
authors.lastname: Taboada
mesh_terms: D000368:Aged; D050197:Atherosclerosis / Q000097:blood* / Q000150:complications / Q000453:epidemiology*; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood* / Q000150:complications / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000097:blood* / Q000150:complications / Q000453:epidemiology*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D014280:Triglycerides